pipette
ESEspañol

Optimizing Lumipulse plasma pTau217/Aβ42 ratio cutpoints in an Asian cohort with high cerebrovascular disease burden

J. R. Chong, A. T. Y. Yam, A. Toh, G. Jiang, T. Ito, C. Kobayashi, A. Dash, P. Sachdev, C. P. Chen, M. K. Lai

PreprintReal-world use

In the authors' words

The generalizability of FDA-cleared Lumipulse plasma pTau217 / A{beta}42 ratio cutpoints to Asian populations remains uncertain, especially in those with high burden of concomitant cerebrovascular disease (CeVD). We evaluated pTau217, A{beta}42 and their ratio in 205 Singapore-based participants with corresponding amyloid neuroimaging. In-house cutpoints were derived using a three-range strategy targeting 95% sensitivity and specificity. Plasma pTau217/A{beta}42 ratio outperformed pTau217 alone (area under the curve, 0.951 versus 0.925; p=0.004), with comparable performance across CeVD severities. Plasma ratio cutpoints achieved 98% negative predictive value, 88% positive predictive value, and 95% accuracy, classifying 10% as intermediate-risk. Using FDA-cleared cutpoints for our cohort retained 97% sensitivity and negative predictive value but yielded lower specificity (86%), positive predictive value (77%) and accuracy (85%), with 29% classified as intermediate-risk. Our findings support the need for population-specific validation of cutpoints from FDA-cleared blood biomarkers of brain amyloid pathology.

Main resultThe abstract does not state a limitation.

Appeared: Saturday, November 7. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.04.26367313